A detailed history of Jpmorgan Chase & CO transactions in Bioventus Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 77,298 shares of BVS stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
77,298
Previous 106,506 27.42%
Holding current value
$1.06 Million
Previous $553,000 19.71%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$3.96 - $6.93 $115,663 - $202,411
-29,208 Reduced 27.42%
77,298 $444,000
Q1 2024

May 10, 2024

BUY
$4.33 - $5.75 $215,188 - $285,757
49,697 Added 87.48%
106,506 $553,000
Q4 2023

Feb 12, 2024

BUY
$2.89 - $5.34 $163,383 - $301,891
56,534 Added 20557.82%
56,809 $299,000
Q3 2023

Nov 14, 2023

SELL
$2.8 - $4.94 $4,211 - $7,429
-1,504 Reduced 84.54%
275 $0
Q2 2023

Aug 11, 2023

SELL
$0.93 - $3.64 $97,165 - $380,303
-104,479 Reduced 98.33%
1,779 $5,000
Q1 2023

May 18, 2023

BUY
$1.07 - $2.95 $26,190 - $72,207
24,477 Added 29.93%
106,258 $113,000
Q1 2023

May 11, 2023

SELL
$1.07 - $2.95 $278,113 - $766,761
-259,919 Reduced 76.07%
81,781 $87,000
Q4 2022

Feb 13, 2023

SELL
$1.81 - $8.14 $19,417 - $87,325
-10,728 Reduced 3.04%
341,700 $892,000
Q3 2022

Nov 14, 2022

SELL
$6.54 - $9.08 $61,181 - $84,943
-9,355 Reduced 2.59%
352,428 $2.47 Million
Q2 2022

Aug 11, 2022

SELL
$6.82 - $13.82 $5,810 - $11,774
-852 Reduced 0.23%
361,783 $2.47 Million
Q1 2022

May 11, 2022

SELL
$11.65 - $15.28 $471,335 - $618,198
-40,458 Reduced 10.04%
362,635 $5.11 Million
Q4 2021

Feb 10, 2022

BUY
$12.37 - $16.77 $440,582 - $597,297
35,617 Added 9.69%
403,093 $5.84 Million
Q3 2021

Nov 12, 2021

BUY
$13.7 - $17.25 $5.03 Million - $6.34 Million
367,476 New
367,476 $5.2 Million

Others Institutions Holding BVS

About Bioventus Inc.


  • Ticker BVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 61,664,200
  • Market Cap $845M
  • Description
  • Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral ner...
More about BVS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.